Multiple Myeloma

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains a clinical trial that looked at the newly approved agent carfilzomib.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on his presentation at the 2010 American Society of Hematology (ASH) conference.

Dr. David Siegel from John Theurer Cancer Center on the Carfilzomib FDA Approval Process

David S. Siegel, MD, PhD, chief, Multiple Myeloma at John Theurer Cancer Center, on the importance of bisphosphonates

The novel agent elotuzumab, when administered with lenalidomide (Revlimid) and dexamethasone, produced responses in 81% of previously treated myeloma patients.

Carfilzomib, described as a next-generation protease inhibitor, produced durable responses in patients with multiple myeloma whose disease relapsed after or proved refractory to all available therapies.

In patients with newly diagnosed multiple myeloma who are candidates for transplant, bortezomib (Velcade) achieved high complete response (CR) rates during induction, delayed disease progression, and improved overall survival (OS).

Treatment advances focus on the potential use of Bortezomib and Lenalidomide in the front-line setting to improve patients' response rates.

The Academy delivers the latest news on biotech and oncoloy research, providing a link between the clinical world of cancer care and the university researchers who are pushing the envelope of knowledge and discovery.

In an oral presentation, Jeffrey A. Zonder, MD, Division of Hematology-Oncology, Karmanos Cancer Center, Wayne State University School of Medicine,Detroit, Michigan, reported updated results of SWOG 0232, a study of lenalidomide (Revlimid) plus dexamethasone compared with dexamethasone alone in patients with newly diagnosed multiple myeloma (MM).

Highlights from the 50th Annual Meeting of the American Society of Hematology.